Physician profile
Russell H Vannorman
NPI 1679576961
$14,577.13
in general payments reported to CMS, 2019-2025
33 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what 83% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,319 · 2020: $2,990 · 2021: $4,062 · 2022: $1,091 · 2023: $1,213 · 2024: $962 · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,988 · Entertainment: $103 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,987.63 |
| Entertainment | $103.03 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $4,647.60 | 2019-2021 | |
| Alcon Vision LLC | $3,434.74 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Glaukos Corporation | $928.97 | 2019-2025 | Idose, Photrexa Viscous and Photrexa, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $713.00 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $664.44 | 2022-2025 | Envista Envy Iol, Miebo, Stellaris |
| Oyster Point Pharma, INC. | $552.47 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $478.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $415.23 | 2019-2023 | |
| Abbvie INC. | $411.44 | 2022-2025 | Lumigan, Durysta |
| Sun Pharmaceutical Industries INC. | $323.98 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $267.77 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $206.76 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $136.21 | 2019-2025 | Oxervate |
| Sight Sciences, INC. | $134.26 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Amgen INC. | $130.36 | 2024-2025 | Tepezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $116.86 | 2019-2021 | |
| Rxsight INC | $110.17 | 2021-2024 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Optos, INC. | $103.03 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| New World Medical,INC. | $99.71 | 2019-2022 | |
| Horizon Therapeutics Plc | $88.06 | 2022-2023 | Tepezza |
| Shire North American Group INC | $77.70 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $73.63 | 2019-2025 | Tecnis Simplicity |
| Ocular Therapeutix, INC. | $65.75 | 2024-2025 | Dextenza |
| Johnson & Johnson Vision Care, INC. | $65.35 | 2019-2024 | |
| Apellis Pharmaceuticals, INC. | $62.65 | 2024-2025 | Syfovre |
| Carl Zeiss Meditec, INC. | $54.30 | 2019 | |
| Rayner Intraocular Lenses Limited | $52.05 | 2022-2023 | Omidria, Rayone Spheric, Rayone Emv |
| Aerie Pharmaceuticals, INC. | $36.31 | 2019-2021 | |
| Harrow Eye, LLC | $33.90 | 2024 | Vevye |
| Thea Pharma INC. | $31.35 | 2022-2025 | Iyuzeh |
| Ivantis, INC | $24.44 | 2021 | |
| Astellas Pharma US INC | $19.64 | 2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $16.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Vannorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.